LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
By Dan Scungio...
By Mike O’Brien...
By Dan Scungio...
While the PGx test is a highly valuable form of medical test, it is also presently one of the most highly scrutinized tests by CMS.